Results 61 to 70 of about 9,316,170 (262)

Urinary neopterin and nitric oxide metabolites as markers of interferon beta-1a activity in primary progressive multiple sclerosis

, 2010
Background: Interferon beta has not been demonstrated to be effective in exploratory phase 2 clinical trials in primary progressive multiple sclerosis.
SM Leary, Thompson, A.J., A. Petzold, Petzold, A.F.S., AJ Thompson, G. Giovannoni, Leary, S.M., Miller, D. H., K. Rejdak, DH Miller, Rejdak, K., Giovannoni, G.   +11 more
core   +1 more source

Analysis of the time to sustained progression in Multiple Sclerosis using generalised linear and additive models [PDF]

, 2003
The course of multiple sclerosis (MS) is generally difficult to predict. This is due to the great inter-individual variability with respect to symptoms and disability status.
Hellriegel, B., Neiss, A., Neiss, Albrecht, Hellriegel, Barbara, Gehrmann, U., Fahrmeir, Ludwig   +5 more
core   +1 more source

Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing–Remitting MS

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) levels are believed to reflect mainly acute and chronic disease processes in multiple sclerosis (MS), respectively. In this study, we investigated whether dimethyl fumarate (DMF) and rituximab (RTX) differentially affect these biomarkers.
F. Shawket, J. Lycke, J. Salzer, F. Piehl, K. Fink, N. Lange, J. Mellergård, C. Malmeström, P. Sundström, I. Erngren, A. al‐Grety, E. Freyhult, K. Kultima, J. Burman, A. Svenningsson   +14 more
wiley   +1 more source

CSF profile in primary progressive multiple sclerosis: Re-exploring the basics.

PLoS ONE, 2017
ObjectiveThe aim of this study was to report the basic cerebrospinal fluid (CSF) profile in patients with primary progressive multiple sclerosis (PPMS).MethodsThe results of CSF analysis from 254 patients with PPMS were collected at four university ...
Ahmed Abdelhak, Tilman Hottenrott, Christoph Mayer, Gudrun Hintereder, Uwe K Zettl, Oliver Stich, Hayrettin Tumani   +6 more
doaj   +1 more source

Evaluation of cognitive assessment and cognitive intervention for people with multiple sclerosis [PDF]

, 2002
Objectives: Cognitive problems in multiple sclerosis are common but any possible benefits of treatment remain uncertain. The aim of the study was to evaluate the benefits of providing a psychology service, including cognitive assessment and intervention,
Weyman, N., Blumhardt, L. D., Blumhardt, L.D., Harding, J., Lincoln, N. B., Dent, A., Nicholl, C., Lincoln, N.B., Playford, E.D., Playford, E. Diane   +9 more
core   +1 more source

Association Between Motor Pathway Damage and Motor Deficit in Upper and Lower Limb in People With MS

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Corticospinal tract damage is common in people with MS, but the degree of clinical symptoms varies. We hypothesize that corticospinal tract lesions are more extensive and severe in people with MS with motor impairments in both upper and lower limbs.
Mathilde Liffran, Malo Gaubert, Alice Dufey, Elise Bannier, Audrey Rico, Jean‐Christophe Ferré, Raphaël Chouteau, Laure Michel, Emmanuelle Le Page, Virginie Callot, Bertrand Audoin, Sarah Demortière, Benoît Combès, Anne Kerbrat   +13 more
wiley   +1 more source

Toxocara infection in the differential diagnosis of multiple sclerosis in the Middle East [PDF]

, 2020
A critical step in the diagnosis of multiple sclerosis is to rule out a heterogeneous variety of multiple sclerosis mimickers, which is crucial in the era of powerful immune-modulator treatments.
El Najjar, Mayssam, El-Ayoubi, Nabil K., Atweh, Samir F., Baalbaki, Marwa M.   +3 more
core   +1 more source

Evaluation of Digital Technologies for Home‐Based Assessment in People With Amyotrophic Lateral Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Digital technologies hold promise for transforming healthcare by enhancing personalized treatments and offer valuable opportunities to improve patient care. Here, we evaluated several novel, self‐administered, home‐based, digital endpoints for their association with corresponding conventional standard clinical measures (primary) in ...
Arne Mueller, Vanessa Vallejo, Mónica Povedano Panadés, Orla Hardiman, Véronique Danel‐Brunaud, Senda Ajroud‐Driss, Philippe Couratier, Jeremy Shefner, Anna Gokey, Mike DiCesare, Erin Lennox, Jens Praestgaard, Lucie Brujin, Peggy Allred, Ram Miller   +14 more
wiley   +1 more source

Unraveling 4‐Phenylbutyrate's Therapeutic Role in SLC6A1 Disorders: Pharmacochaperoning Over HDAC Inhibition

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Variants in SLC6A1, encoding the GABA transporter 1 (GAT‐1), cause epilepsy, autism spectrum disorder, and developmental delay via loss of GABA uptake, impaired trafficking, and ER retention. We previously found that 4‐Phenylbutyrate (PBA), an FDA‐approved drug, restores GABA uptake and reduces seizures in SLC6A1‐related disorders ...
Melissa B. DeLeeuw, Karishma Randhave, Ekta Anand, Ziang (Debbie) Song, Wangzhen Shen, Jing‐Qiong Kang   +5 more
wiley   +1 more source

Severe late‐onset neutropenia induced by ocrelizumab in a multiple sclerosis patient: A case report

Clinical Case Reports, 2022
Ocrelizumab is a recombinant humanized antibody targeted against CD‐20 molecule, which was approved for the treatment of relapsing and primary progressive multiple sclerosis.
Robin Rauniyar, Rahul Rauniyar, Ankita Agrawal, Shikha Yadav, Sreekant Avula   +4 more
doaj   +1 more source